Table 1 Demographic and clinical features of the SSc patients
From: Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study
Variable | Patients with SSc (n 70) |
|---|---|
Gender (F/M), (%) | 65/5 (92.9/7.1) |
RP duration (years), mean ± SD | 5.10 ± 6.15 |
Disease duration (years), mean ± SD | 9.41 ± 6.26 |
Cutaneous subset (Diffuse/Limited), n (%) | 25/45 (35.7/64.3) |
Modified Rodnan cutaneous score | 13.11 ± 10.55 |
Calcinosis, n (%) | 11 (15.7) |
Telangiectasias, n (%) | 38 (54.3) |
Active digital ulcers, n (%) | 14 (20.0) |
Arthritis, n (%) | 20 (28.6) |
Esophageal involvement, n (%) | 53 (75.7) |
FVC < 70% predicted, n (%) | 19 (27.1) |
Interstitial lung involvement on CT scan, n (%) | 34 (48.6) |
PAH, n (%) | 7 (10.0) |
Renal crisis, n (%) | 3 (4.3) |
C-reactive protein (mg/L) | 8.81 ± 8.97 |
ACA, n (%) | 28 (40.0) |
Anti-Scl-70, n (%) | 21 (30.0) |
Anti-RNA polymerase III, n (%) | 5 (7.1) |
IgG anti-cardiolipin | 2 (2.9) |
IgM anti-cardiolipin | 3 (4.3) |
IgG anti-beta 2 glycoprotein 1 | 0 (0.0) |
IgM anti-beta 2 glycoprotein 1 | 1 (1.4) |
Lupus anticoagulant | 0 (0.0) |